Vaccination against meningococcus in complement-deficient individuals.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. A glycoconjugate vaccine for Neisseria meningitidis induces antibodies in human infants that afford protection against meningococcal bacteremia in a neonate rat challenge model.Infection and immunity · 2002
   Trial
2. Recurrent meningococcal meningitis with complement 6 (C6) deficiency: A case report.Medicine · 2020
   Article
3. Antibody-mediated complement activation in pathology and protection.Immunology and cell biology · 2020
   Review
4. Exome sequencing in routine diagnostics: a generic test for 254 patients with primary immunodeficiencies.Genome medicine · 2019
   Article
5. Modern complement analysis.Clinical and diagnostic laboratory immunology · 2003
   Review
6. Development of antibodies against tetravalent meningococcal polysaccharides in revaccinated complement-deficient patients.Clinical and experimental immunology · 2000
   Article
7. Molecular mechanisms of complement component C6 deficiency; a hypervariable exon 6 region responsible for three of six reported defects.Clinical and experimental immunology · 2000
   Review
8. Properdin deficiency and meningococcal disease--identifying those most at risk.Clinical and experimental immunology · 1999
   Review

Corrections and comments

• Comment on
  Protection against meningococcal serogroup ACYW disease in complement-deficient individuals vaccinated with the tetravalent meningococcal capsular polysaccharide vaccine.1998

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as